ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target
13 juin 2023 08h07 HE
|
ZyVersa Therapeutics
White paper summarizes the research of leading inflammasome experts, Drs. Helen Bramlett, Juan Pablo de Rivero Vaccari, W. Dalton Dietrich, and Robert W. Keane, University of Miami Miller School of...
Monoclonal Antibodies Market Size & Share to Surpass $155.2 Billion by 2028 | Vantage Market Research
10 avr. 2023 05h10 HE
|
Vantage Market Research
WASHINGTON, April 10, 2023 (GLOBE NEWSWIRE) -- The Global Monoclonal Antibodies Market is valued at USD 111.93 Billion in 2022 and is projected to reach a value of USD 186.67 Billion by 2030 at a...
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
26 juil. 2022 08h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH ZUG, Switzerland, July 26, 2022 – MoonLake Immunotherapeutics AG (MoonLake; Nasdaq:...
Global Monoclonal Antibodies Market is Expected to Reach $390.58 Billion by 2030: Says AMR
20 juil. 2021 08h34 HE
|
Allied Market Research
Portland, OR, July 20, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Monoclonal Antibodies Market was estimated at $146.64 billion in 2020 and is...
180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics
26 mars 2021 08h30 HE
|
180 Life Sciences Corp.
NEW YORK, March 26, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – 180 Life Sciences Corp. (NASDAQ: ATNF) announces the availability of a broadcast titled, “Controlling Inflammation to Stop Disease.” ...
Infusion Therapy Market To Reach USD 10.98 Billion By 2027 | Reports and Data
11 mars 2020 11h00 HE
|
Reports and Data
New York, March 11, 2020 (GLOBE NEWSWIRE) -- The Global Infusion therapy market is forecast to reach USD 10.98 Billion by 2027, according to a new report by Reports and Data. Infusion therapy is...
Global Immune-Mediated Inflammatory Diseases (IMIDs) Treatment Market to Witness CAGR of 6.3% during 2018– 2024: Energias Market Research Pvt. Ltd.
23 mars 2018 07h00 HE
|
Energias Market Research
NEW YORK, March 23, 2018 (GLOBE NEWSWIRE) -- Global Immune-Mediated Inflammatory Diseases (IMIDs) Treatment market size is expected to reach, USD 153.5 Billion in 2024, at a CAGR of 6.3% from 2018...
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
08 juin 2015 21h12 HE
|
Mesoblast
NEW YORK and MELBOURNE, Australia, June 8, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic...
Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study
12 mai 2015 05h08 HE
|
Mesoblast
NEW YORK, May 12, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its...
Rafarma (RAFA) Enters $50,000,000 Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
06 juin 2013 09h18 HE
|
Rafarma Pharmaceuticals, Inc.
SANDY, Utah, June 6, 2013 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. (the "Company") (Pink Sheets:RAFA) announces commencement of production of the antibiotic Ceftriaxone.
Ceftriaxone treats...